Clinical Trial Applications - Stopped: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Stopped | |
|---|---|---|---|---|---|
11. |
ECCT/23/10/06 | CONSTELLATION A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium longum, B. infantis) supplementation versus placebo on weight gain in underweight infants |
Principal Investigator(s) 1. Dr Godfrey Allan Otieno 2. Dr Videlis Nduba Site(s) in Kenya 1. KEMRI-Kondele Children’s Hospital (Kisumu county) 2. KEMRI CRDR Clinical Research Annex (Nairobi City county) |
Not recorded |
View |
12. |
ECCT/23/09/04 | GBT440-038Open-Label Extension An Open-Label Extension Study of Voxelotor Administered Orally to Participants with Sickle Cell Disease Who Have Participated in Voxelotor Clinical Trials |
Principal Investigator(s) 1. Jessie Nyokabi Githanga 2. Videlis Nduba 3. Bernhards Ragama Ogutu Site(s) in Kenya 1. Gertrude’s Children Hospital (Nairobi City county) 2. Kenya Medical Research Institute (KEMRI), Centre for Respiratory Diseases Research (CRDR) (Nairobi City county) 3. KEMRI CRDR SIAYA within Siaya County Referral Hospital Grounds (Siaya county) 4. Strathmore University Medical Center, Centre for Research in Therapeutic Sciences (Nairobi City county) |
Not recorded |
View |
13. |
ECCT/23/10/04 | ACCEDE OR Study Use of Continuous glucose monitoring devices among Type 1 diabetes patients followed up in CDiC clinics in Machakos, Nairobi and Kiambu counties in Kenya: A three-arm pragmatic study on effectiveness, feasibility, acceptability, and cost |
Principal Investigator(s) 1. Daniel Katambo Kiningu Site(s) in Kenya 1. Machakos Level 5 Hospital (Machakos county) 2. Thika Level 5 Hospital (Kiambu county) 3. Kenya Diabetes Management and Information Centre (Machakos county) |
Not recorded |
View |
14. |
ECCT/23/09/03 | CONSTELLATION A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium longum, B. infantis) supplementation versus placebo on weight gain in underweight infants |
Principal Investigator(s) 1. Dr Simon Kariuki Site(s) in Kenya 1. Kenya Medical Research Institute- Centre for Global Health Research (Kisumu county) |
Not recorded |
View |
15. |
ECCT/23/04/01 | mRNA-1273-P203 A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age |
Principal Investigator(s) 1. Dr Janet Oyieko Site(s) in Kenya 1. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county) 2. KEMRI CRDR - Clinical Research Nairobi (Nairobi City county) 3. KEMRI/USAMRD (Kericho county) 4. Victoria Biomedical Research Institute (Kisumu county) 5. Kenya Medical Research Institute/USAMRU (Kisumu county) 6. KEMRI CMR-Kar Geno Research Centre (Kisumu county) 7. KEMRI/ CDC (Kisumu county) 8. KEMRI (Kisumu county) 9. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county) |
Not recorded |
View |
16. |
ECCT/23/03/04 | CONSTELLATION A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium longum, B. infantis) supplementation versus placebo on weight gain in underweight infants |
Principal Investigator(s) 1. Dr Lucas Otieno Tina Site(s) in Kenya 1. Victoria Biomedical Research Institute (Kisumu county) |
Not recorded |
View |
17. |
ECCT/23/05/05 | mRNA-1273-P203 A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age |
Principal Investigator(s) 1. Videlis Nduba Site(s) in Kenya 1. KEMRI CRDR - Clinical Research Nairobi (Nairobi City county) 2. KEMRI/USAMRD (Kericho county) 3. Victoria Biomedical Research Institute (Kisumu county) 4. Kenya Medical Research Institute/USAMRU (Kisumu county) 5. KEMRI CMR-Kar Geno Research Centre (Kisumu county) 6. KEMRI/ CDC (Kisumu county) 7. KEMRI (Kisumu county) 8. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county) 9. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county) |
Not recorded |
View |
18. |
ECCT/23/02/04 | mRNA-1273-P203 A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age |
Principal Investigator(s) 1. Dr Victor Mudhune Site(s) in Kenya 1. Victoria Biomedical Research Institute (Kisumu county) 2. KEMRI/USAMRD (Kericho county) 3. Kenya Medical Research Institute/USAMRU (Kisumu county) 4. KEMRI CMR-Kar Geno Research Centre (Kisumu county) 5. KEMRI CMR-Kar Geno Research Centre (Kisumu county) 6. KEMRI CRDR - Clinical Research Nairobi (Nairobi City county) 7. KEMRI/ CDC (Kisumu county) 8. KEMRI (Kisumu county) 9. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county) 10. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county) |
Not recorded |
View |
19. |
ECCT/23/03/03 | Moderna 1273 A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age |
Principal Investigator(s) 1. Prof. Walter Godfrey Jaoko Jaoko Site(s) in Kenya 1. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county) 2. Victoria Biomedical Research Institute (Kisumu county) 3. KEMRI/USAMRD (Kericho county) 4. Kenya Medical Research Institute/USAMRU (Kisumu county) 5. KEMRI CMR-Kar Geno Research Centre (Kisumu county) 6. KEMRI CRDR - Clinical Research Nairobi (Nairobi City county) 7. KEMRI/ CDC (Kisumu county) 8. KEMRI (Kisumu county) 9. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county) |
Not recorded |
View |
20. |
ECCT/23/03/02 | Sunrise-3 A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19 |
Principal Investigator(s) 1. Dr. Paul Yonga 2. Dr John Kinuthia 3. DR LUCAS OTIENO TINA Site(s) in Kenya 1. Fountain Projects and Research Office, Clinical Research Centre (FOPRO-CRC) (Kisumu county) 2. KENYATTA NATIONAL HOSPITAL (Nairobi City county) 3. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) |
Not recorded |
View |